

NEWSLETTER

THE HUMMINGBIRD

Colibri Scientific

In This Issue

Strategic Relationships

**New Premises
Covid Supply Issues**

Industry News

Colibri Scientific

+44 7796 188 923

charles.stewart@colibriscientific.co.uk

Deanway 6, Wilmslow Rd, Handforth,

Wilmslow, SK9 3HW

www.colibriscientific.co.uk

ABOUT

Welcome to The Hummingbird.

The Hummingbird will keep you informed on our evolving and growing business as well as share current industry hot topics.

Subscribe and follow us on LinkedIn and Twitter so you don't miss out on anything!

Contact

charles.stewart@colibriscientific.co.uk

with any suggestions of what you would like to see in future editions.



Follow us.....



STRATEGIC RELATIONSHIP

We are very excited to announce that we have been selected by Avacta Life Sciences to enter a strategic relationship for the provision of global sample management services to support Avacta's clinical development portfolio.

We are delighted to be working with Avacta Life Sciences, Therapeutics Division and are very much looking forward to a successful partnership.

**"Avacta Life Sciences
and Colibri Scientific
form a strategic
relationship."**



NEW PREMISES

After months of preparation and planning to ensure our services weren't disrupted, we have now completed our move to Deanway, and a new building to call our own, relocating our headquarters to exciting new premises in Wilmslow.

The building will allow us to organically grow the business and enable us to increase our service offering to clients.

The new lab furniture for our sample preparation lab is still in manufacture and is due for installation later this month, however, the lab is fully functional with existing facilities.

Although we have moved we will be keeping a presence at Alderley Park.

Follow us.....



Fit out and build works have now been completed so that the building met our exact requirements to provide:

- Kitting facility with increased capacity of 300%.
- Separate QC room to facilitate improved workflow management.
- Sample preparation laboratory.
- Freezer room with separate ring mains and power back up.
- Project Management and meeting room suite
- Electronically managed stock room.
- Logistics facility



Follow us.....



CONSUMABLES SUPPLY ISSUES

You may have seen on the news that there is a global shortage of plastic consumables, particularly blood collection tubes (BCTs), which could have a knock-on effect for clinical trials.

Colibri can report that we have established excellent supply links for all standard BCTs and plastic consumables and have considerably increased holding stock values. We also have provided an option to our clients to 'ring-fence' stock for their particular study.

Our stock control team, headed by Alice Cross, have done an amazing job in adapting the stock management role from simply maintaining stock and batch numbers to becoming true sourcing specialists. With the challenges of Covid-19 as well as Brexit, being able to say that stock issues have had zero effect on delivery to our clients' studies is something that Alice and her team should be extremely proud of.



Follow us.....



INDUSTRY NEWS

MODERNA SET TO START HUMAN TRIALS OF EXPERIMENTAL MRNA HIV VACCINE

According to clinicaltrials.gov, Moderna could start a Phase I trial of its mRNA HIV Vaccine in the coming weeks.

Moderna are looking for 56 uninfected adults in good general health to start their Phase I trial evaluating the safety and Immunogenicity of the mRNA vaccine.

Moderna will be using the same nanotechnology used in their highly effective covid vaccine.

According to United Nations data, there were 37.7 million people living with HIV around the world in 2020. Moderna will be the first to use mRNA technology with the view to creating a vaccine for HIV and researchers hope that the success of the Covid-19 Vaccination can be replicated with HIV.

For more information visit:

<https://clinicaltrials.gov/ct2/show/NCT05001373>



Follow us.....



PFIZER, NOVARTIS SIGN ON TO ACCELERATE GENE THERAPIES FOR RARE DISEASES WITH US AGENCIES

A cadre of big and small biotechs and pharmas, plus nonprofit organizations, have signed on to a new U.S. initiative to go after gene therapies for rare diseases.

Called the Bespoke Gene Therapy Consortium, or BGTC, the initiative is headed up by the FDA and the National Institutes of Health (NIH) and is designed to accelerate development of gene therapies. The agencies are putting up \$76 million over five years.

On the list of companies are Biogen, Johnson & Johnson's Janssen pharmaceutical unit, Pfizer, the Novartis Institutes for BioMedical Research, Regenxbio, Spark Therapeutics, Takeda, Taysha Gene Therapies, Thermo Fisher Scientific and Ultragenyx. The Alliance for Regenerative Medicine, the American Society of Gene and Cell Therapy and other groups are also involved.

To read the full article visit:

<https://www.fiercebiotech.com/biotech/pfizer-j-j-among-pharmas-and-biotechs-signing-to-us-agencies-new-rare-disease-gene-therapy>



Follow us.....



'NATURAL KILLER' CELL TREATMENT RAISES QUESTIONS.


Fate Therapeutics reported new results for two early-stage studies testing two different types of experimental lymphoma treatments that utilize natural killer cells, a fast-emerging form of cancer immunotherapy.

Eight of 11 lymphoma patients who received one Fate NK cell therapy, FT516, have shown evidence of a response, as have 10 of 14 given another known as FT596. No serious neurological side effects were reported, and only two Grade 1 or Grade 2 cases of the immune-related adverse events typically associated with other forms of engineered cell therapy were observed.

Still, it's unclear how well Fate's NK cell treatments stack up to more proven T cell-based therapies. Five of the eight responses to FT516 held up after a median of close to six months, for instance. And only one of those patients' cancers has been in remission for that long, a key potency measure for cell therapies. Fate shares were down about 11% in pre-market trading Friday morning.

To read the full article please visit biopharmdive:

<https://www.biopharmadive.com/news/fate-therapeutics-lymphoma-nk-cell-therapy-results/605322/>



Follow us.....

